NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RUKOBIA (fostemsavir tromethamine) is an oral extended-release small molecule attachment inhibitor approved in 2020 for treatment-experienced HIV-1 patients with multi-drug resistant virus. It represents a novel mechanism of action targeting HIV entry and is indicated for heavily treatment-experienced patients with limited therapeutic options.
$0.091BPart D
Peak3.1 years to LOEPeak lifecycle stage indicates mature commercial organization with established market presence and stable team structure supporting ~10K annual claims.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on RUKOBIA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.